세계의 비치료용 생체분자 시장 보고서(2023년)

“Non-Therapeutic Biomolecules Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-therapeutic biomolecules market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-therapeutic biomolecules? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The non-therapeutic biomolecules market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Trad Pharma: Enzymes; Recombinant Proteins; Plasmids; Peptides; Oligonucleotides; Monoclonal Antibodies

• 2) By End User: Research; Pharma; In vitro diagnostics(IVD)

• Companies Mentioned: Merck Group; Bio-Synthesis Inc.; Eurogentec; Aviva Systems Biology; RayBiotech

• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

• Time series: Five years historic and ten years forecast.

• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the non-therapeutic biomolecules market are Merck Group, Bio-Synthesis Inc., Eurogentec, Aviva Systems Biology, RayBiotech, Biocon Limited, Bio-Techne Corporation, Danaher Corporation, Eurofins Scientific SE, Thermo Fisher Scientific Inc., Agilent Technologies Inc., GE HealthCare, GeneDesign Inc., Biosearch Technologies, TriLink BioTechnologies LLC, ATDBio Ltd., ABI Scientific, Abbiotec Inc., ACES Pharma, Activotec, Alta Bioscience Ltd., Bachem Holding, CanPeptide, CASLO ApS, and CPC Scientific Inc.

The global non-therapeutic biomolecules market is expected to grow from $25.02 billion in 2022 to $27.91 billion in 2023 at a compound annual growth rate (CAGR) of 11.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The non-therapeutic biomolecule market is expected to reach $41.26 billion in 2027 at a CAGR of 10.3%.

The non-therapeutic biomolecule market consists of sales of monosaccharides, disaccharides, polysaccharides, heteropolysaccharides, structural proteins, hormones, respiratory pigments, storage proteins, toxins, deoxyribonucleic acids (DNA), ribonucleic acids (RNA), fatty acids, phospholipids, steroids, eicosanoids, and glycolipids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Non-therapeutic biomolecule refers to the organic compounds created by cells and living things. These compounds come in a wide range of shapes and sizes and carry out a wide variety of tasks in body functioning.

Asia-Pacific was the largest region in the non-therapeutic biomolecules market in 2022. The regions covered in the non-therapeutic biomolecule report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of trad pharma of non-therapeutic biomolecules are enzymes, recombinant proteins, plasmids, peptides, oligonucleotides, and monoclonal antibodies. Enzymes are globular conjugated proteins that catalyze biological reactions by reducing the activation energy that increases the rate of the reaction. These are used by various end users such as research, pharma and In vitro diagnostics(IVD).

The rapidly increasing number of research and laboratory testing is expected to propel the growth of the non-therapeutic biomolecules market going forward. Laboratory testing refers to the medical procedure that involves testing a sample of blood, urine, or other substance from the body to determine and monitoring of disease and draft a treatment plan, whereas research refers to the new knowledge is created or current knowledge is creatively applied to produce new concepts, theories, and understandings. Non-therapeutic biomolecules in laboratory testing are used to measure the presence or concentration of a biomarker molecule that indicates disease, to enhance the sensitivity and specificity of the test. For instance, in 2020, according to the National Center for Science and Engineering Statistics, a US-based government statistical agency, research and development spending by academic institutions totaled $86.4 billion in the year 2020 with an increase of $2.7 billion (3.3%) as compared to the last year. Additionally, according to the American Association for Clinical Chemistry (AACC), a US-based scientific and medical professional organization, more than 200,000 laboratories certified under the Clinical Laboratory Improvement Amendment (CLIA) execute almost 13 billion laboratory tests in the US each year, and laboratory services comprise 2.3% of U.S. healthcare expenditures and two percent of medicare expenditures. Therefore, the rapidly increasing number of research and laboratory testing is driving the growth of the non-therapeutic biomolecules market.

Product innovations are a key trend gaining popularity in the non-therapeutic biomolecules market. Major companies operating in the market are focused on research and development for product innovations to sustain their position in the market. For instance, in January 2022, BASF SE, a Germany-based multinational chemical company partnered with Caregen, a Korean-based company operating in biomimetic peptide research and development, and introduced the Peptovitae™ series manufactured using liposome-encapsulation technology to expand its dermo-cosmetics portfolio to address a broad range of skin concerns with innovative and differentiated solutions. Liposomal encapsulation is a technique that uses fats to deliver essential vitamins or medications to specific body sections in tiny bubbles without affecting other body parts. The Peptovitae™ series addresses a wider range of skin concerns than are traditionally associated with the use of peptides such as signs of aging, enhancing the brightness of the skin, soothing skin prone to dryness and itching, and moisturizing skin.

In July 2021, Eli Lilly and Company, a US-based multinational pharmaceut`ical company acquired Protomer Technologies for $1 billion. Through this acquisition, Eli Lilly and Company aims to strengthen its product portfolio in biomolecules and accelerate the development of these next-generation therapeutics. Protomer Technologies is a US-based manufacturing and engineering of peptide molecules, including non-therapeutics molecule.

The countries covered in the non-therapeutic biomolecule market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The non-therapeutic biomolecules market research report is one of a series of new reports from The Business Research Company that provides non-therapeutic biomolecules market statistics, including the non-therapeutic biomolecules industry's global market size, regional shares, competitors with a non-therapeutic biomolecules market share, detailed non-therapeutic biomolecules market segments, market trends, and opportunities, and any further data you may need to thrive in the non-therapeutic biomolecules industry. This non-therapeutic biomolecules market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Table of Contents

1. Executive Summary

2. Non-Therapeutic Biomolecules Market Characteristics

3. Non-Therapeutic Biomolecules Market Trends And Strategies

4. Non-Therapeutic Biomolecules Market - Macro Economic Scenario

• 4.1. COVID-19 Impact On Non-Therapeutic Biomolecules Market
• 4.2. Ukraine-Russia War Impact On Non-Therapeutic Biomolecules Market
• 4.3. Impact Of High Inflation On Non-Therapeutic Biomolecules Market

5. Non-Therapeutic Biomolecules Market Size And Growth

• 5.1. Global Non-Therapeutic Biomolecules Historic Market, 2017-2022, $ Billion
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints On The Market
• 5.2. Global Non-Therapeutic Biomolecules Forecast Market, 2022-2027F, 2032F, $ Billion
  • 5.2.1. Drivers Of The Market
  • 5.2.2. Restraints On the Market

6. Non-Therapeutic Biomolecules Market Segmentation

• 6.1. Global Non-Therapeutic Biomolecules Market, Segmentation By Trad Pharma, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Enzymes
• Recombinant Proteins
• Plasmids
• Peptides
• Oligonucleotides
• Monoclonal Antibodies
• 6.2. Global Non-Therapeutic Biomolecules Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Research
• Pharma
• In vitro diagnostics(IVD)

7. Non-Therapeutic Biomolecules Market Regional And Country Analysis

• 7.1. Global Non-Therapeutic Biomolecules Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 7.2. Global Non-Therapeutic Biomolecules Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Non-Therapeutic Biomolecules Market

• 8.1. Asia-Pacific Non-Therapeutic Biomolecules Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Non-Therapeutic Biomolecules Market, Segmentation By Trad Pharma, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 8.3. Asia-Pacific Non-Therapeutic Biomolecules Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Non-Therapeutic Biomolecules Market

• 9.1. China Non-Therapeutic Biomolecules Market Overview
• 9.2. China Non-Therapeutic Biomolecules Market, Segmentation By Trad Pharma, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
• 9.3. China Non-Therapeutic Biomolecules Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Non-Therapeutic Biomolecules Market

• 10.1. India Non-Therapeutic Biomolecules Market, Segmentation By Trad Pharma, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 10.2. India Non-Therapeutic Biomolecules Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Non-Therapeutic Biomolecules Market

• 11.1. Japan Non-Therapeutic Biomolecules Market, Segmentation By Trad Pharma, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 11.2. Japan Non-Therapeutic Biomolecules Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Non-Therapeutic Biomolecules Market

• 12.1. Australia Non-Therapeutic Biomolecules Market, Segmentation By Trad Pharma, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 12.2. Australia Non-Therapeutic Biomolecules Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Non-Therapeutic Biomolecules Market

• 13.1. Indonesia Non-Therapeutic Biomolecules Market, Segmentation By Trad Pharma, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 13.2. Indonesia Non-Therapeutic Biomolecules Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Non-Therapeutic Biomolecules Market

• 14.1. South Korea Non-Therapeutic Biomolecules Market, Segmentation By Trad Pharma, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 14.2. South Korea Non-Therapeutic Biomolecules Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Non-Therapeutic Biomolecules Market

• 15.1. Western Europe Non-Therapeutic Biomolecules Market Overview
• 15.2. Western Europe Non-Therapeutic Biomolecules Market, Segmentation By Trad Pharma, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 15.3. Western Europe Non-Therapeutic Biomolecules Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Non-Therapeutic Biomolecules Market

• 16.1. UK Non-Therapeutic Biomolecules Market, Segmentation By Trad Pharma, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 16.2. UK Non-Therapeutic Biomolecules Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Non-Therapeutic Biomolecules Market

• 17.1. Germany Non-Therapeutic Biomolecules Market, Segmentation By Trad Pharma, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 17.2. Germany Non-Therapeutic Biomolecules Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Non-Therapeutic Biomolecules Market

• 18.1. France Non-Therapeutic Biomolecules Market, Segmentation By Trad Pharma, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 18.2. France Non-Therapeutic Biomolecules Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Non-Therapeutic Biomolecules Market

• 19.1. Eastern Europe Non-Therapeutic Biomolecules Market Overview
• 19.2. Eastern Europe Non-Therapeutic Biomolecules Market, Segmentation By Trad Pharma, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 19.3. Eastern Europe Non-Therapeutic Biomolecules Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Non-Therapeutic Biomolecules Market

• 20.1. Russia Non-Therapeutic Biomolecules Market, Segmentation By Trad Pharma, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 20.2. Russia Non-Therapeutic Biomolecules Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Non-Therapeutic Biomolecules Market

• 21.1. North America Non-Therapeutic Biomolecules Market Overview
• 21.2. North America Non-Therapeutic Biomolecules Market, Segmentation By Trad Pharma, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 21.3. North America Non-Therapeutic Biomolecules Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Non-Therapeutic Biomolecules Market

• 22.1. USA Non-Therapeutic Biomolecules Market Overview
• 22.2. USA Non-Therapeutic Biomolecules Market, Segmentation By Trad Pharma, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 22.3. USA Non-Therapeutic Biomolecules Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Non-Therapeutic Biomolecules Market

• 23.1. South America Non-Therapeutic Biomolecules Market Overview
• 23.2. South America Non-Therapeutic Biomolecules Market, Segmentation By Trad Pharma, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 23.3. South America Non-Therapeutic Biomolecules Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Non-Therapeutic Biomolecules Market

• 24.1. Brazil Non-Therapeutic Biomolecules Market, Segmentation By Trad Pharma, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 24.2. Brazil Non-Therapeutic Biomolecules Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Non-Therapeutic Biomolecules Market

• 25.1. Middle East Non-Therapeutic Biomolecules Market Overview
• 25.2. Middle East Non-Therapeutic Biomolecules Market, Segmentation By Trad Pharma, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 25.3. Middle East Non-Therapeutic Biomolecules Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Non-Therapeutic Biomolecules Market

• 26.1. Africa Non-Therapeutic Biomolecules Market Overview
• 26.2. Africa Non-Therapeutic Biomolecules Market, Segmentation By Trad Pharma, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 26.3. Africa Non-Therapeutic Biomolecules Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Non-Therapeutic Biomolecules Market Competitive Landscape And Company Profiles

• 27.1. Non-Therapeutic Biomolecules Market Competitive Landscape
• 27.2. Non-Therapeutic Biomolecules Market Company Profiles
  • 27.2.1. Merck Group
    • 27.2.1.1. Overview
    • 27.2.1.2. Products and Services
    • 27.2.1.3. Strategy
    • 27.2.1.4. Financial Performance
  • 27.2.2. Bio-Synthesis Inc.
    • 27.2.2.1. Overview
    • 27.2.2.2. Products and Services
    • 27.2.2.3. Strategy
    • 27.2.2.4. Financial Performance
  • 27.2.3. Eurogentec
    • 27.2.3.1. Overview
    • 27.2.3.2. Products and Services
    • 27.2.3.3. Strategy
    • 27.2.3.4. Financial Performance
  • 27.2.4. Aviva Systems Biology
    • 27.2.4.1. Overview
    • 27.2.4.2. Products and Services
    • 27.2.4.3. Strategy
    • 27.2.4.4. Financial Performance
  • 27.2.5. RayBiotech
    • 27.2.5.1. Overview
    • 27.2.5.2. Products and Services
    • 27.2.5.3. Strategy
    • 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Non-Therapeutic Biomolecules Market

29. Non-Therapeutic Biomolecules Market Future Outlook and Potential Analysis

30. Appendix

• 30.1. Abbreviations
• 30.2. Currencies
• 30.3. Historic And Forecast Inflation Rates
• 30.4. Research Inquiries
• 30.5. The Business Research Company
• 30.6. Copyright And Disclaimer